Skip to content

Johnson & Johnson

pharmaNew Brunswick, NJ
Trials
0
Subs
0
People
0
Links
5

Executive Summary

AI synthesis

Johnson & Johnson is a major US multinational pharmaceutical and medical device company headquartered in New Brunswick, NJ, with clear BIOSECURE status. As a leading Big Pharma player with extensive R&D capabilities and global reach, J&J typically pursues large-scale strategic partnerships and acquisitions. The company has strong therapeutic focus areas including oncology, immunology, and neuroscience, making it an attractive partner for innovative biotechs. Limited available data suggests this may be an incomplete profile requiring additional research.

Structure: J&J operates as a traditional US publicly traded corporation with multiple subsidiary layers across pharmaceutical, medical device, and consumer health divisions. The corporate structure is straightforward for US due diligence purposes without complex VIE arrangements or foreign holding company complications.

Ownership & Shareholder Structure

Legend Biotech Johnson & Johnson

deal_partner

J&J-Legend Carvykti (cilta-cel). First China CAR-T with FDA approval.

Pharmaron Johnson & Johnson

personnel

Boliang Lou (Pharmaron founder, Columbia PhD) — key J&J CRO relationship.

Burning Rock Biotech Johnson & Johnson

deal_partner

Burning Rock genomic diagnostics partnership with J&J for precision oncology.

WuXi AppTec Johnson & Johnson

cdmo_client

WuXi provides integrated CRO/CDMO services to J&J.

Tigermed Johnson & Johnson

cdmo_client

Tigermed provides clinical operations to J&J in China.

BIOSECURE Risk

low

US-headquartered company with clear BIOSECURE status and no BCC designation

Mitigation: No BIOSECURE mitigation required as US entity with clear status

BD Intelligence

Pipeline Strength8/10
Deal Readiness9/10

Therapeutic Areas:

oncologyimmunologyneurosciencecardiovascular

Recent Deals: No recent deal activity data available in profile

Approach: Engage through senior BD leadership with focus on strategic partnerships rather than opportunistic deals

Red Flags

  • Incomplete data profile with missing key personnel, subsidiary, and recent events information
  • Profile appears to incorrectly categorize J&J as Chinese company in context

Quick Facts

Key People
0
Subsidiaries
0
CDMO/CRO Subs
0
Genomics Subs
0
Direct BIOSECURE
0
Corp Events
0
Gov-Connected
0
Clinical Trials
0
Publications
0
Drug Molecules
0
Relationships
5

Sources & Methodology

Clinical trials data: ClinicalTrials.gov API v2 (0 trials linked to this entity)

SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)

Publications: Europe PMC API (0 publications indexed)

Drug molecules: ChEMBL database (European Bioinformatics Institute)

Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)

Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures

Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)

Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.